PL3360864T3 - Związek pirymidynowy - Google Patents

Związek pirymidynowy

Info

Publication number
PL3360864T3
PL3360864T3 PL16853686T PL16853686T PL3360864T3 PL 3360864 T3 PL3360864 T3 PL 3360864T3 PL 16853686 T PL16853686 T PL 16853686T PL 16853686 T PL16853686 T PL 16853686T PL 3360864 T3 PL3360864 T3 PL 3360864T3
Authority
PL
Poland
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PL16853686T
Other languages
English (en)
Inventor
Hidenori Kimura
Hitoshi Ban
Yoshiaki Isobe
Hitoshi Watanabe
Original Assignee
Sumitomo Dainippon Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co., Ltd. filed Critical Sumitomo Dainippon Pharma Co., Ltd.
Publication of PL3360864T3 publication Critical patent/PL3360864T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
PL16853686T 2015-10-07 2016-10-06 Związek pirymidynowy PL3360864T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015199750 2015-10-07
EP16853686.0A EP3360864B1 (en) 2015-10-07 2016-10-06 Pyrimidine compound
PCT/JP2016/079756 WO2017061532A1 (ja) 2015-10-07 2016-10-06 ピリミジン化合物

Publications (1)

Publication Number Publication Date
PL3360864T3 true PL3360864T3 (pl) 2021-10-25

Family

ID=58487860

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16853686T PL3360864T3 (pl) 2015-10-07 2016-10-06 Związek pirymidynowy
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu

Country Status (20)

Country Link
US (5) US10632192B2 (pl)
EP (2) EP3868741B1 (pl)
JP (3) JP6769976B2 (pl)
KR (1) KR102651207B1 (pl)
CN (1) CN108290845B (pl)
AU (1) AU2016334826B2 (pl)
CA (1) CA3001283C (pl)
CY (1) CY1124542T1 (pl)
DK (2) DK3360864T3 (pl)
ES (2) ES2960724T3 (pl)
FI (1) FI3868741T3 (pl)
HU (2) HUE064322T2 (pl)
MY (1) MY194902A (pl)
PH (1) PH12018500755A1 (pl)
PL (2) PL3360864T3 (pl)
PT (2) PT3360864T (pl)
RU (1) RU2759917C2 (pl)
SG (1) SG11201802832UA (pl)
TW (1) TWI718188B (pl)
WO (1) WO2017061532A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
PL3554474T3 (pl) * 2016-12-16 2024-04-15 Baxter International Inc. Kompozycje mykafunginy
FI3603619T3 (fi) 2017-03-29 2025-09-25 Sumitomo Pharma Co Ltd Rokoteadjuvanttiformulaatio
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
MX2021000951A (es) * 2018-07-23 2021-06-23 Sumitomo Pharma Co Ltd Composición que contiene vacuna contra la influenza.
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
AU2019413182B2 (en) * 2018-12-26 2026-02-12 Sumitomo Pharma Co., Ltd. Preparation including vaccine adjuvant
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CA3136182A1 (en) 2019-04-05 2020-10-08 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
PH12022552536A1 (en) * 2020-03-27 2022-11-14 Univ Nat Corp Ehime Univ Malaria transmission-blocking vaccines
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN121311513A (zh) * 2023-04-12 2026-01-09 住友制药株式会社 葡聚糖与tlr7激动剂的缀合物
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ATE267175T1 (de) 1998-08-27 2004-06-15 Sumitomo Pharma Pyrimidin derivate
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
US7799800B2 (en) 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
BRPI0919937A2 (pt) 2008-10-24 2016-02-16 Glaxosmithkline Biolog Sa composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
SG173617A1 (en) 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
JP5206513B2 (ja) 2009-03-12 2013-06-12 オムロンヘルスケア株式会社 機能追加モジュール
JP5913093B2 (ja) * 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
CA2768195A1 (en) 2009-08-07 2011-02-10 Glaxosmithkline Biologicals Sa Lipidated oxoadenine derivatives
US20130202629A1 (en) 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
CA2808624C (en) * 2010-08-17 2019-05-14 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
EP2640716A1 (en) * 2010-11-19 2013-09-25 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
MX2014002949A (es) 2011-09-20 2014-04-30 Hoffmann La Roche Compuesto de imidazopiridina, composiciones y metodos de uso.
AU2013261267B2 (en) * 2012-05-18 2017-06-29 Sumitomo Pharma Co., Ltd. Carboxylic acid compounds
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound

Also Published As

Publication number Publication date
JP6769976B2 (ja) 2020-10-14
HUE064322T2 (hu) 2024-03-28
CN108290845B (zh) 2021-08-03
DK3868741T3 (da) 2023-11-06
EP3360864B1 (en) 2021-04-28
MY194902A (en) 2022-12-22
ES2870679T3 (es) 2021-10-27
TWI718188B (zh) 2021-02-11
US11266738B2 (en) 2022-03-08
PT3868741T (pt) 2023-10-19
CN108290845A (zh) 2018-07-17
AU2016334826A1 (en) 2018-05-10
JP7195398B2 (ja) 2022-12-23
US20180280499A1 (en) 2018-10-04
FI3868741T3 (fi) 2023-10-02
PH12018500755A1 (en) 2018-10-15
HK1255921A1 (en) 2019-09-06
RU2018116351A3 (pl) 2020-02-25
US20260053911A1 (en) 2026-02-26
RU2759917C2 (ru) 2021-11-18
TW201718518A (zh) 2017-06-01
US20240245766A1 (en) 2024-07-25
PL3868741T3 (pl) 2024-01-29
US20220226468A1 (en) 2022-07-21
CA3001283A1 (en) 2017-04-13
US11911466B2 (en) 2024-02-27
EP3868741A1 (en) 2021-08-25
JPWO2017061532A1 (ja) 2018-08-02
US12440560B2 (en) 2025-10-14
HUE055079T2 (hu) 2021-10-28
RU2018116351A (ru) 2019-11-07
JP2022010266A (ja) 2022-01-14
JP2021001210A (ja) 2021-01-07
WO2017061532A1 (ja) 2017-04-13
CA3001283C (en) 2023-10-10
KR20180056774A (ko) 2018-05-29
CY1124542T1 (el) 2022-07-22
PT3360864T (pt) 2021-06-02
US20210008197A1 (en) 2021-01-14
EP3868741B1 (en) 2023-08-30
SG11201802832UA (en) 2018-05-30
EP3360864A4 (en) 2019-05-29
EP3360864A1 (en) 2018-08-15
KR102651207B1 (ko) 2024-03-25
US10632192B2 (en) 2020-04-28
AU2016334826B2 (en) 2020-08-27
DK3360864T3 (da) 2021-06-14
ES2960724T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
PL3360864T3 (pl) Związek pirymidynowy
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3627029T3 (da) Manipulationssikret låg
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
PT3298027T (pt) Compostos depsipéptidos antelmínticos
IL265166B (en) Anti-influenza virus pyrimidine derivatives
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
KR20180084876A (ko) 내플라즈마성 부재
EP3435660A4 (en) HEAD-MOUNTED DISPLAY
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
SMT202200173T1 (it) Composti
EP3372588A4 (en) pyrimidine
HUE054351T2 (hu) Vegyületek
DK3597189T3 (da) Krystallinske forbindelser
DE112015006486A5 (de) Inkubationsrinne
BR112018001062A2 (pt) compostos inovadores
EP3372589A4 (en) pyrimidine derivative
DK3347403T3 (da) Polyalkoxyfedtforbindelse
EP3346592A4 (en) Rotating machine
DE102015206660A8 (de) Plattenaufteilanlage
LT3331885T (lt) Junginiai
EP3454107A4 (en) HEAD MOUNTED DISPLAY
DE112015005906A5 (de) Gurtschlossbringer
DK3630729T3 (da) Pyrimidinforbindelse